Summary
Guardant Health, Inc. (GH) filed an 8-K on August 6, 2019, primarily to report its financial results for the fiscal quarter ended June 30, 2019. The key information was disclosed via a press release furnished as Exhibit 99.1. While the 8-K itself doesn't contain detailed financial figures, it serves as the official notification of the company's performance during that period. Investors should refer to the furnished press release for specific revenue, earnings, and operational metrics. This filing is crucial for understanding Guardant Health's progress in the second quarter of 2019. Investors would be looking for updates on sales growth, particularly from their liquid biopsy tests, progress in clinical adoption, and any forward-looking guidance. The nature of this filing indicates that the company is meeting its reporting obligations and providing timely updates on its financial condition and operational results to the market.
Key Highlights
- 1Guardant Health filed an 8-K on August 6, 2019, to announce Q2 2019 financial results.
- 2The financial results were provided via a press release furnished as Exhibit 99.1.
- 3Investors should consult the press release (Exhibit 99.1) for specific financial and operational details for the quarter ended June 30, 2019.
- 4The filing confirms the company is reporting its quarterly performance.
- 5Information furnished in the 8-K, including the press release, is generally not considered 'filed' for liability purposes under Section 18 of the Exchange Act unless explicitly incorporated by reference.
- 6This report is a standard disclosure for publicly traded companies to update investors on their performance.